Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,348 recruiting studies in this area right now.
By phase
- Not applicable9,612
- Phase 24,442
- Phase 12,685
- Phase 1/Phase 21,654
- Phase 31,400
- Phase 2/Phase 3287
- Phase 4268
Top conditions
- Breast Cancer1,207
- Prostate Cancer648
- Cancer636
- Colorectal Cancer476
- Lung Cancer421
- Ovarian Cancer341
- Multiple Myeloma329
- Pancreatic Cancer288
- Gastric Cancer285
- Acute Myeloid Leukemia283
- Hepatocellular Carcinoma259
- Solid Tumor245
- Advanced Solid Tumor231
- Head and Neck Cancer227
- Cervical Cancer225
- Endometrial Cancer213
- Advanced Solid Tumors208
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center458
- Fudan University306
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital129
Where studies are running
- California1,401
- Texas636
- Arizona508
- Florida439
- Alabama430
- New York406
- Massachusetts340
- Maryland330
- New Jersey275
- Pennsylvania236
Recruiting studies20,348 total
- NCT01048281Recruiting
Study of stomach and esophagus cancer samples
This study looks at stomach (gastric) and esophagus cancer, using clinical information and tissue samples. It may help researchers better understand these cancers and improve future care.
Stanford, CaliforniaAges 18 years+ - NCT05134779Recruiting
Study aims to tailor cancer treatment to your biology
This study looks at how genes, the cancer environment, and your immune system interact to develop treatments that work better for people with breast cancer. It may help researchers learn why some treatments work for certain people and not others.
New York, New YorkAges 18–90 - NCT02993900Recruiting
Brachytherapy guided by imaging for gynecologic cancers
This study tests image-guided internal radiation (brachytherapy) for certain gynecologic cancers. It may help deliver radiation more precisely by using scans done close to enrollment.
Baltimore, MarylandAges 18–100 - NCT04395495Recruiting
RASopathy disorder study biobank for kids and families
This study collects and stores health samples and information from people with RASopathy conditions (like Noonan or Costello syndromes) and from family members who may not have the condition. It helps researchers understand these disorders and supports future studies that could lead to better care.
Cincinnati, OhioAges Any age - NCT04543201Recruiting
Telehealth help planning your future care after high-grade brain cancer
This trial offers video visits to help people newly diagnosed with a high-grade glioma (a serious brain tumor) talk through their future care preferences. It aims to support “advanced directives,” meaning documenting the kind of care you want if you can’t speak for yourself later.
Rochester, New YorkAges 18 years+ - NCT05192122RecruitingPhase 1
Stop maintenance medicine in multiple myeloma with low remaining disease
This early-phase study looks at whether it’s safe to stop the usual “maintenance” medicine after a strong response in multiple myeloma. It aims to see if stopping treatment for people with very low remaining disease reduces drug exposure without allowing relapse too soon.
Chicago, IllinoisAges 18 years+ - NCT05317819RecruitingPhase 3
Test ADI-PEG 20 versus placebo for advanced liver cancer
This study tests whether ADI-PEG 20 helps people with advanced, unresectable hepatocellular carcinoma (liver cancer) who have high arginine levels. Participants get ADI-PEG 20 or a placebo to see which works better and improves outcomes.
ChanghuaAges 18–99 - NCT05389423RecruitingPhase 1
Pomalidomide plus chemotherapy for HIV-related lymphoma
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
Bethesda, MarylandAges 18–120 - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Duarte, CaliforniaAges 18 years+ - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Los Angeles, CaliforniaAges 12 years+ - NCT05398783Recruiting
Study of how metabolism and body composition change over time
This natural history study follows people to understand how metabolism and body composition vary in health and disease. It may help researchers better measure metabolic changes and understand who is at risk as health and treatments change.
Bethesda, MarylandAges 2–99 - NCT05382338RecruitingPhase 3
Sodium thiosulfate to protect hearing in medulloblastoma
This Phase 3 study tests whether adding sodium thiosulfate during treatment for newly diagnosed medulloblastoma can reduce the risk of hearing loss. It is designed for children and teens whose cancer meets specific low-risk or average-risk tumor and lab features.
Birmingham, AlabamaAges 4–21 - NCT05371808Recruiting
Early vs delayed treatment for high-risk CLL: cost study
This study compares early treatment versus delaying treatment in newly diagnosed people with high-risk CLL/SLL who feel well. It mainly looks at the overall “costs and value” of each approach and asks patients to complete short health and quality-of-life questionnaires.
Vancouver, British ColumbiaAges 18 years+ - NCT05413850RecruitingPhase 1/Phase 2
Lu-177 PSMA drug study for advanced prostate cancer
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Miami, FloridaAges 18 years+ - NCT05413421RecruitingPhase 1
ORIC-944 for metastatic prostate cancer after hormone therapy
This early-phase trial tests ORIC-944 to see how well it works and what dose is safest for metastatic prostate cancer that has progressed after hormone-targeted pills. It may help people whose cancer has stopped responding to prior prostate cancer hormone treatments.
Colorado Springs, ColoradoAges 18 years+ - NCT05410145RecruitingPhase 1/Phase 2
Study drug for advanced KRAS G12C solid tumors
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
Orange, CaliforniaAges 18 years+ - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Orange, CaliforniaAges 18 years+ - NCT05363280RecruitingPhase 2
Second-treatment study for lung or kidney cancer after initial therapy
This Phase 2 study tests a new treatment for people with small cell lung cancer, non-small cell lung cancer, or kidney cancer after they have finished their first main treatment. It may help shrink tumors or control the cancer further.
Birmingham, AlabamaAges 18 years+ - NCT05367635RecruitingPhase 1
Testing a new drug for advanced stomach cancers with CLDN18.2
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Birmingham, AlabamaAges 18 years+ - NCT05365581RecruitingPhase 1
Study drug for stomach and pancreatic cancers with lab-checked targets
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
Orange, CaliforniaAges 18 years+ - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Duarte, CaliforniaAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Orange, CaliforniaAges 12 years+ - NCT05394714RecruitingPhase 1
Magicell-NK cell therapy after colon cancer surgery
This early-stage trial tests an individualized immune cell treatment (Magicell-NK) made from your own cells to help prevent colon cancer from coming back after surgery. It studies safety and how well the treatment works in people with early-stage colon cancer.
TaoyuanAges 20 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,348 recruiting oncology studies from the U.S. registry right now, out of 31,535 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.